Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 November 2023 | Story Leonie Bolleurs | Photo Francois van Vuuren
UFS empowers through Human Settlements Training Programme
At the graduation ceremony for the Free State Provincial Department of Human Settlements, were from the left, front: Caren Somiah, Director: Housing Capacity, Building and Partnerships in the Free State Department of Human Settlements; Kagisho Motlhanke, Housing Coordinator at the Mangaung Metro; back: Thomas Stewart, Senior Lecturer in the UFS Department of Urban and Regional Planning; Dr Kgosi Mocwagae, Head of the UFS Department of Urban and Regional Planning; Adv Moferefere Dhlamini, Chief of Staff in the Office of the MEC; Sello Senoge, Matjhabeng Municipality; and Cyril Monyela, Deputy Director-General in the Free State Department of Human Settlements.

The Department of Urban and Regional Planning at the University of the Free State (UFS) hosted a certification ceremony for the Free State Provincial Department of Human Settlements on the Bloemfontein Campus on 30 October 2023.

A group of 40 officials from municipalities and the Provincial Department of Human Settlements were awarded certificates for completing four short learning programmes (SLPs) in Human Settlements, offered by the Department of Urban and Regional Planning. The training was conducted between November 2022 and May 2023.

Sustainable human settlements

“The overall aim of this training was to equip the participants to play a constructive role in human settlements in their respective places of employment,” said Dr Kgosi Mocwagae, Head of the Department of Urban and Regional Planning at the UFS. 

This is in line with the mission of the department to deliver – through excellent teaching and scholarship – competent urban and regional planners who will contribute to the creation of sustainable human settlements and improve the quality of life, particularly in Africa.

Dr Mocwagae reflected on the training presented, stating that it aimed to achieve several key objectives, including enhancing participants' understanding of the institutional framework governing the development and management of human settlements. It also sought to nurture a sensitivity to the principles of sustainable human settlement development, considering factors such as climate change, the Sustainable Development Goals (SDGs), local legislation, and best practices. Additionally, the training placed significant emphasis on the importance and processes involved in upgrading informal settlements. Furthermore, it aimed to empower participants with the necessary skills to structure a proposal for the enhancement of informal settlements within the current legislative and administrative frameworks applicable in South Africa.

Building capacity

Cyril Monyela, the Deputy Director General in the Free State Department of Human Settlements, delivered the keynote address, congratulating the cohort of officials on their remarkable achievement.

In his address, he referred to the various pieces of legislation that have emerged over the years and emphasised the need for capacity to implement human settlement sector programmes, ensuring that millions of informal households in South Africa have access to decent shelter. Enhancing sector capacity by developing the skills of staff is one of the department's primary institutional objectives.

“It is the first of many skills courses designed to enable and ensure that practitioners in the Free State Department of Human Settlements execute the department’s mandate,” he stated.

The event concluded with an address from Advocate Shirly Hyland, Director of the Kovsie Phahamisa Academy. According to her, it is important to remember where one comes from, but it is also key to focus on our future. “Witnessing plans that originated in the 1950s coming to fruition, while not perfect yet, is encouraging and instils hope in South Africans regarding the progress being made,” she remarked. 

Adv Hyland referenced a quote from a corporate giant, ‘You are not your work, and your work is not you.’ “For you, this is not the case. Those of you who work in human settlements – your work literally follows you home. Human settlements affect every person from every sphere of life. The right to adequate housing is enshrined in the Bill of Rights, and with the expertise you have learned in these programmes, you have been equipped with the knowledge and power to bring this human right to life.”

“In completing this short learning programme, you have been entrusted with a critical task. You get to contribute to an environment in which citizens live and thrive. The environment where a veggie garden can feed a community; the environment in which the Protea or Bafana Bafana national teams can nurture their talents; and the environment in which the leaders of tomorrow are born and raised,” she said. 

In her final remarks, Adv Hyland referred to a quote from former President Nelson Mandela about education being the most powerful weapon one can use to change the world. “And this is exactly what you are doing. You have worked hard,” she said, urging the group of practitioners to change the world, one human settlement at a time. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept